Nektar price target raised to $95 from $70 at Wedbush

Wedbush raised the firm’s price target on Nektar (NKTR) to $95 from $70 and keeps a Neutral rating on the shares. The firm notes Nektar reported deepening responses in 52-week maintenance follow-up for Phase 2 REZOLVE-AA. Results combined patients who maintained blinded treatment during extension, and patients who were withdrawn from treatment. Wedbush is cautiously optimistic on prospects in alopecia, but remains concerned on market penetration for the company’s separate program in atopic dermatitis.